Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ — Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin pathway will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which will be held virtually December 5-8, 2020.

Details of the presentations are as follows:

Abstract Number: 1690
Title: DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin
Date: Sunday, December 6, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster II
Presenter: Vu Hong, PhD, Director and Project Leader

Abstract Number: 2599
Title: DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced Hypoferremia
Date: Monday, December 7, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster III
Presenter: Maria Beconi, PhD, SVP of Translational Research and Development

Full abstracts are currently available through the ASH conference website: www.hematology.org/Annual-Meeting/Abstracts/.

About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

SOURCE Disc Medicine

Related Links

http://www.discmedicine.com

Source Article

Read more

Fauci: Trump has not been to a task force meeting in months

President TrumpDonald John TrumpMore than 300 military family members endorse Biden Five takeaways from the final Trump-Biden debate Biden: ‘I would transition from the oil industry’ MORE has not been to a White House coronavirus task force meeting in several months, Anthony FauciAnthony FauciTrump, Biden clash over coronavirus response, mounting death toll Stahl tells Pence he and Trump ‘insulted 60 Minutes’ by giving ‘campaign speeches’ How Trump lost to the coronavirus MORE said Friday.

During an interview on “Meet the Press Daily,” the nation’s top infectious disease doctor said he hasn’t directly interacted with or spoken to Trump in some time.

“I definitely don’t have his ear as much as Scott Atlas right now, that has been a changing situation,” Fauci said. 

Scott Atlas is a neuroradiologist and a fellow at the Hoover Institution, a conservative think tank. He was added to the task force over the summer after appearing frequently on Fox News.

Atlas has emerged as one of Trump’s most influential advisers, but he has come under fire from public health experts inside and outside the administration who accuse him of feeding the president — and the public — misinformation.

Fauci said he meets virtually with the heads of federal health agencies, such as Centers for Disease Control and Prevention Director Robert Redfield, Food and Drug Administration Commissioner Stephen Hahn, as well as task force coordinator Deborah BirxDeborah BirxScott Atlas: Fauci ‘just one person on the task force’ Overnight Health Care: Trump takes criticism of Fauci to a new level | GOP Health Committee chairman defends Fauci | Birx confronted Pence about Atlas Birx confronted Pence about Atlas MORE.

Fauci said that during the spring, the task force would meet almost every day, but once the focus of the White House shifted to the economics of reopening the country, the frequency of official task force meetings has dropped to once a week.

Fauci said most of his interactions with the White House now are with Vice President Pence.

“We certainly interact with the vice president at the task force meetings, and the vice president makes our feelings known to the president, but direct involvement with the president and discussions, I have not done that in a while,” Fauci said.

Fauci said the country is in a “precarious” position, and people really need to understand how difficult the winter will be if coronavirus infections continue to spike the way they are now.

The United States on Thursday reported at least 75,049 new coronavirus cases, the second-highest daily total so far. 

“We don’t want to shut the country down. Every time I talk about things that we need to do, people get concerned. We’re not talking about shutting down, but we’re talking about doubling down on some of the fundamental public health measures that we need to adhere to,” Fauci said, like the universal wearing of masks, physical distancing, avoiding large crowds and indoor dining.

“They seem rather simple, but they really do work,” he said.

Read more

Guidelines for approving a coronavirus vaccine will be the focus of FDA advisers meeting Thursday

The vaccine advisory committee, meeting remotely in an all-day session, will not review a specific vaccine because no company has applied for the FDA’s imprimatur. Rather, the group will provide views on the FDA’s standards governing whether a vaccine is sufficiently safe and effective to warrant an emergency use authorization. It will also weigh in on the conduct of clinical trials once a vaccine is cleared and monitoring safety on an ongoing basis.

Even a general discussion is an important milestone, especially after protracted political melodrama involving the vaccine review process, experts said.

“The visual of scientists sitting around the table carefully discussing what a safe and effective vaccine might look like is an important moment for the FDA,” said Jason L. Schwartz, assistant professor of health policy and management at the Yale School of Public Health. “For months, all the FDA could do was offer promises about how science would guide its decisions on the vaccine. This shows how that will happen as data begins to come in.”

The panel will offer the agency advice for navigating the “extraordinary and unprecedented steps” of clearing a vaccine on an emergency basis, said M. Miles Braun, former director of the FDA’s division of epidemiology and an adjunct professor at the Georgetown University School of Medicine, during a media briefing Wednesday. FDA officials will want to know they are “on firm ground, and not missing any issues,” Braun said.

The FDA has said it will hold additional advisory committee meetings to consider applications from vaccine makers, which could begin arriving as soon as mid-November.

The panel, called the Vaccines and Related Biological Products Advisory Committee, is made up mostly of academic experts in infectious diseases, immunology and biostatistics. Some members recused themselves because they work at hospitals where coronavirus vaccine trials are being conducted or are involved in the trials. They were replaced by temporary members, including Arnold Monto, a University of Michigan epidemiologist who will serve as committee chairman, according to documents on the FDA website.

The FDA on Wednesday posted the topics it wants to discuss with the committee, including the effects of vaccines in specific populations. One of the most complicated questions centers on how to continue clinical trials after a vaccine is authorized. Should participants who received the placebo be notified and allowed to get the vaccine? If so, will that hurt the trial’s ability to collect useful data on an ongoing basis, and how can that be mitigated?

The FDA has used advisory committees for decades to bulk up its expertise and win buy-in from the public and outside scientists on its decisions. The FDA is not required to take advice from the panels but often does. The vaccine committee is expected to play an especially important role given the political pressure exerted by the White House on the FDA in recent weeks and months.

The White House held up the guidance, but the FDA circumvented the blockade by publishing it as part of briefing materials provided

Read more

Biodesix Announces Data from Three Studies on Lung Nodule Diagnosis and Management to be Shared at CHEST Annual Meeting 2020

Research Evaluates Risk Classification for Patients with Lung Nodules

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, recently published data from three clinical studies, which found important new information on diagnosis and management of lung nodules. Data from these studies, which are being presented at the American College of Chest Physicians (CHEST) annual meeting, demonstrate the value of the Nodify Lung™ testing strategy and confirm previously reported performance of the Nodify XL2® and Nodify CDT™ tests.

Abstract #A1464/Poster #P1319: Identification of Likely Malignant Indeterminate Pulmonary Nodules by Analysis of Autoantibodies Against Lung Cancer-Associated Antigens
Authors: Kevin Doubleday, James Jett, Laura Peek, Trevor Pitcher
A retrospective analysis of the PANOPTIC study found that the blood-based Nodify CDT test accurately identified patients whose lung nodules were likely malignant, which confirms previously reported test performance. Patients identified as Nodify CDT positive may benefit from a more rapid evaluation and intervention for cancer.

Abstract #A1468/Poster #P1325: Lung Nodule Integrated Classifier Biomarker: First Data with Real-World Clinical Use
Authors: James Jett, Kerstin Pohl, Gerard Silvestri, Steven Springmeyer
A real-world clinical use study demonstrates the utility of the blood-based Nodify XL2 test for identifying patients with likely benign lung nodules by integrating the patients’ blood-based protein data with clinical risk factors, resulting in a large proportion of low to moderate risk nodules being reclassified as very low risk. Risk reclassification can reduce invasive procedures on benign nodules and ultimately lead to improved nodule management.

Abstract #A1476/Poster #P1324: Use of Two Blood-Based Biomarker Tests in Series to Reclassify Risk of Indeterminate Pulmonary Nodules
Authors: Kevin Doubleday, James Jett, Laura Peek, Trevor Pitcher, Steven Springmeyer
Data suggest that while standard risk assessment for lung cancer is imprecise, it can be improved with the blood-based Nodify Lung testing strategy. By combining the Nodify CDT and Nodify XL2 tests, patients can be more appropriately assessed for risk of malignancy to help reduce unnecessary procedures on patients with benign nodules and delays in treatment for patients with cancer.

About Biodesix
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung™ nodule risk assessment testing strategy, consisting of the Nodify XL2™ and the Nodify CDT™ tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges

Read more

How Physical Fitness Training Boosts Resilience by Meeting Targets

Exercise not only rejuvenates healthy mind and body but also helps in fulfilling the targets of individual in several working fields. Fitness freaks who are indulged in different activities always prefer to take proper training from an instructor who can make them perfect in different categories like sports, jobs (Army, Navy) and different martial arts like Judo, Kung fu, and Karate. They seek the assistance of trainer because it is hard for them to set such objectives themselves.

Physical fitness training improves your performance in several categories of work. Intense workout and athletic body with resilience are essential for fields like army, police, navy, airlines and sports. Fitness guidance or training may help to fulfill one's target in those platforms.

Psychological Benefits of the Workout

Research has shown that exercise not only builds your body but also handles stress and anxiety. Physically active people have a lower rate of depression and other psychological issues. Some of the psychometric benefits of workouts are highlighted below:

  • Workouts can improve your mood.
  • Reduces symptoms or risk of depression and protects you from illness like hypertension and other mental disorders.
  • Sharpens the decision-making capacity of an individual.
  • Rejuvenates the power of endurance and increase inner solace.

Physical Benefit of Exercise

There are multiple benefits of physical activity if done in a correct way. Advantages of workouts are as follows:

  • Exercise controls weight and gives a proper shape of your body by balancing the Body Mass Index.
  • Health issues like diabetes, metabolic syndrome, high blood pressure, cholesterol, heart disease etc can be controlled by physical activities.
  • Fitness activity helps in strengthening muscles, bones, and joints.
  • It increases the chance of living longer.
  • Workout also helps to overcome insomnia and provide good sleep.

Physical Fitness Training Goals

Everyone has the idea about the benefits of a workout but few people are acquainted with the side affect of wrong exercise, which can be the major reason for multiple health issues or injuries. If you do not take proper guidance of a professional fitness instructor then it may be hard to meet the fitness goals. Following are the guidelines suggested by the fitness gurus:

  • They set up regular workouts.
  • Instructors always try to guide their clients through important steps and techniques to prevent injury while training.
  • Fitness trainers make their clients strong in the specific platforms of working by scheduling the appropriate workouts for their jobs or other activities.
  • For beginners, some steps are designed by the trainers so that the trainee does not feel difficulty in a workout routine.
  • Fitness instructors do not give overtraining, which may harm a beginner.
  • They suggest you follow a balanced diet chart according to the BMI of your body.
  • They make you start exercise with warm up and stretching.

Indulging in various types of physical activities may not offer fruitful result if you do not take professional guidance. Therefore, lessons provided by physical fitness training can be beneficial and help to reach the target in a specific time and boosts resilience …

Read more